RAP 0.00% 20.5¢ resapp health limited

A new Beginning..., page-2727

  1. 3,464 Posts.
    lightbulb Created with Sketch. 956
    Yes, I got the same reply from Brian, and a more detailed reply from Tony.

    However, in this latest quarterly no update on the Australian Adult trial or Home OSAS sleep study trial. I will have to rely on what Tony stated in his January 2019 press release and which he also stated in his most recent conference call ...

    "ResApp has two other major clinical programs underway; an acute adult respiratory disease diagnosis study in which clinical adjudication is expected to finish this quarter and an at-home obstructive sleep apnoea study in which recruitment is nearly complete. As announced previously, a technical issue prevented clinical adjudication for croup in ResApp’s acute paediatric respiratory disease diagnosis study in the US, SMARTCOUGH-C-2, however this has been resolved and adjudication is expected to be completed this quarter".

    Tomorrow in the beginning of the last month of the quarter for the above .

    It is possible that news on the above may be released any time now...

    MB
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.